CA Patent

CA3101323A1 — Dosing regimen for the treatment of pi3k related disorders

Assigned to Incyte Corp · Expires 2019-12-05 · 6y expired

What this patent protects

The present application provides methods of treating PI3Kd related disorders using pyrazolopyrimidine derivatives.

USPTO Abstract

The present application provides methods of treating PI3Kd related disorders using pyrazolopyrimidine derivatives.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CA3101323A1
Jurisdiction: CA
Classification: —
Expires: 2019-12-05
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.